Document is current
Any future updates will be listed below
-
Authors
Quon, Doris V. https://orcid.org/0000-0002-9148-3268
Escobar, Miguel https://orcid.org/0000-0002-2944-0240
Boggio, Lisa https://orcid.org/0009-0002-2997-3757
Corrales-Medina, Fernando F. https://orcid.org/0000-0001-6185-4809
Jain, Akshat https://orcid.org/0000-0001-6433-7997
Reding, Mark T. https://orcid.org/0000-0003-3319-2806
Sidonio, Robert F. Jr. https://orcid.org/0000-0002-9509-9415
Staber, Janice M. https://orcid.org/0000-0002-2738-4206
Charlet, Jessica https://orcid.org/0009-0000-5596-397X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05036278 at ClinicalTrials.govDocuments that mention this clinical trial
A New Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia A: Results from the PREDICT Study
https://doi.org/10.1007/s12325-026-03560-0
-
Funding
Funding for this research was provided by:
Bayer
- License Information
-
More Information
Article History
Received: 8 January 2026
Accepted: 2 March 2026
First Online: 26 March 2026
Declarations
:
: Doris V. Quon: Bayer, Biomarin Pharmaceutical Inc., CSL Behring, Hema Biologics/LFB, Genentech/Roche, Novo Nordisk, Pfizer, Sanofi, Takeda. Miguel Escobar: Genentech, HEMA Biologics, LFB, Novo Nordisk, Sanofi, Takeda, uniQure, BioMarin, CSL Behring, Kedrion, NHF, Pfizer. Lisa Boggio: Regeneron, Kedrion, Novo Nordisk, Octapharma, Sanofi, Alnylam, Genentech. Fernando F. Corrales-Medina: Genentech, Novo Nordisk, Octapharma, Bayer (consultancy), Takeda, Sanofi. Akshat Jain: NovoNordisk, Sanofi, Pfizer, Bayer (Speaker); Pfizer, Beam Therapeutics (grant funding); End point adjudication committee (Beam, Genetix). Mark T. Reding: Institutional research support: Bayer, Be Biopharma, Biomarin. Advisory board: Bayer, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Sanofi, Spark, Takeda; Speaker bureau: Bayer, CSL Behring, Sanofi, Takeda. Robert F. Sidonio, Jr: Advisory board: Bayer, Genentech, Roche, HEMA Biologics, LFB, Novo Nordisk, Sanofi, Sobi, Takeda, Octapharma, Alnylam and HEMAb. IIS: Takeda, LFB, HEMA Biologics, Octapharma. Other: ATHN Chair, HFA medical advisor. Janice Staber: Bayer, BioMarin, Genentech, NovoNordisk, Sanofi. Jessica Charlet: Current Bayer employee.
: The results presented in this article are based on the PREDICT study. All procedures performed in the study were in accordance with the ethical standards of the local institutional review board (IRB) for each site and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The central IRB was WCG and their reference number is 20215317. Written informed consent was obtained from all participants before study participation.
